These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10921397)

  • 21. Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation.
    Zanaga LP; Vigani AG; Angerami RN; Giorgetti A; Escanhoela CA; Ataíde EC; Boin IF; Stucchi RS
    Braz J Med Biol Res; 2017 Jan; 50(1):e5540. PubMed ID: 28076451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
    Blanco JR; Rivero-Juárez A
    Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
    [No Abstract]   [Full Text] [Related]  

  • 23. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C and interferon: fewer cases of liver cancer.
    Prescrire Int; 2013 Jul; 22(140):191. PubMed ID: 23951600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
    Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
    J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful Interferon Therapy Reverses Enhanced Hepatic Progenitor Cell Activation in Patients with Chronic Hepatitis C.
    Noritake H; Kobayashi Y; Ooba Y; Matsunaga E; Ohta K; Shimoyama S; Yamazaki S; Chida T; Kawata K; Sakaguchi T; Suda T
    J Interferon Cytokine Res; 2015 Dec; 35(12):956-62. PubMed ID: 26308703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H; Lok AS
    Antivir Ther; 2011; 16(6):787-95. PubMed ID: 21900710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?
    D'Ambrosio R; Colombo M
    Liver Int; 2016 Jun; 36(6):783-90. PubMed ID: 26936383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant diffuse large B-cell lymphoma and hepatocellular carcinoma in chronic hepatitis C virus liver disease: a study of two cases.
    Lin A; Kadam JS; Bodenheimer HC; Leonard J; Joyce MA; Lake-Bakaar G
    J Med Virol; 2008 Aug; 80(8):1350-3. PubMed ID: 18551608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 35. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
    Kim GA; Han S; Kim HD; An J; Lim YS
    J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Nakai K; Saito T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Intervirology; 2003; 46(5):296-307. PubMed ID: 14555850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of interferon therapy in "non responder" patients with chronic hepatitis C.
    Poynard T; Moussali J; Ratziu V; Regimbeau C; Opolon P
    J Hepatol; 1999; 31 Suppl 1():178-83. PubMed ID: 10622583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin.
    Vukotic R; Gramenzi A; Vitale G; Cursaro C; Serra C; Biselli M; Scuteri A; Andreone P; Bernardi M
    Liver Int; 2008 Mar; 28(3):407-11. PubMed ID: 17900241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.